Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
40S ribosomal protein S23 (RPS23) is a structural protein component of the small (40S) subunit of cytoplasmic ribosomes, which are responsible for catalyzing protein synthesis in eukaryotic cells[1][3][10]. RPS23 belongs to the S12P family of ribosomal proteins and plays a critical role in ensuring translational accuracy and the proper assembly of the small ribosomal subunit (SSU), participating in RNA binding and ribosome structure formation[1][10]. It is evolutionarily conserved, showing significant similarity with the yeast ribosomal protein S28. Mutations in RPS23 have been linked to rare developmental disorders such as brachycephaly, trichomegaly, and developmental delay, as well as associations with autism spectrum disorder, but RPS23 itself is not generally considered a direct therapeutic target or biomarker in drug discovery[1][5][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 40S ribosomal protein S23 (RPS23).